Medical Equipment

Cancer Biomarker Industry Anticipated to Expand at 15.9% CAGR During the Forecast Period

November 17, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Cancer Biomarker Market By 2029?

The market for cancer biomarkers has experienced considerable expansion lately, with projections indicating a rise from $22.19 billion in 2024 to $25.09 billion the following year, reflecting a 13.1% compound annual growth rate during this span; this upward trajectory during the past period is largely credited to the increasing adoption of tailored medical treatments, advancements in immunotherapies, changes in governmental regulations, joint research activities, and a growing emphasis on non-coding RNA studies.

Anticipation surrounds the cancer biomarker sector, projecting substantial expansion throughout the impending years, culminating in a market valuation of $45.33 billion by 2029, underpinned by a compound annual growth rate (CAGR) of 15.9%. This accelerated development throughout the projection timeframe stems from several key factors, notably the evolving emphasis on diagnostics tailored to individual patients, the incorporation of biomarkers into the rigors of clinical investigations, the proliferation of sophisticated panels featuring multiple biomarkers, ongoing research into non-coding RNA elements, and the successful market introduction of various biomarker assays. Key directional shifts observed during this period encompass significant progress in genomic technologies, the wider adoption of precision medicine strategies, the rising prominence of liquid biopsy techniques, advancements in immunotherapy modalities, and the increasing integration of artificial intelligence (AI) capabilities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Industry Drivers Are Expected To Accelerate The Cancer Biomarker Market From 2025 To 2029?

The increasing prevalence of cancer is the primary factor fueling the expansion of the cancer biomarker sector. Cancer incidence is defined as the quantification of novel cancers of a particular type or location arising within a specified population over the course of one year, typically expressed as the count of cancers per 100,000 individuals susceptible to the disease. Escalating cancer cases necessitate the broader application of cancer biomarkers, given their utility in evaluating potential disease risk, detecting hidden malignant growths, distinguishing between non-cancerous and cancerous characteristics, or differentiating between various types of cancer. Illustratively, data released in January 2022 by the American Cancer Society, a healthcare authority based in the United States, projected 1.9 million new cancer diagnoses and 609,360 cancer-related fatalities across the US for that year, effectively equating to approximately 1,670 deaths daily. Consequently, the upward trend in cancer occurrences is anticipated to stimulate market growth for cancer biomarkers in the foreseeable future.

What Are The Emerging Segments Gaining Attention In The Cancer Biomarker Market?

The cancer biomarkermarket covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What Long-Term Trends Will Shape The Future Growth Of The Cancer Biomarker Industry?

Leading entities within the cancer biomarker sector are concentrating their efforts on engineering novel offerings, specifically those integrating artificial intelligence for cancer diagnostics, aiming to elevate the precision of disease identification and tailor therapeutic strategies for individuals receiving care. AI-driven cancer biomarkers represent biological signals associated with malignancy that are uncovered and assessed employing sophisticated artificial intelligence methodologies. To illustrate, in the month of September in 2023, the United States firm, Ibex Medical Analytics, introduced Galen Breast HER2, an AI-enabled application developed to boost both the correctness and consistency in assigning HER2 scores for individuals diagnosed with breast cancer. This sophisticated system assists medical examiners by automatically pinpointing malignant tumor regions and measuring the level of HER2 expression, strictly adhering to the standards set forth in the 2018 ASCO/CAP guidelines. Employing a fresh computational sequence, the Galen Breast HER2 apparatus scrutinizes slides stained via immunohistochemistry (IHC), furnishing comprehensive visual representations of the staining characteristics which empowers pathologists to arrive at sound therapeutic choices.

Who Are The Top Performing Companies In The Cancer Biomarker Market In Recent Years?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

What Regional Growth Trends Are Shaping The Cancer Biomarker Market Outlook?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Biomarker Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

Browse Through More Reports Similar to the Global Cancer Biomarker Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795